Five years after having proton therapy for early- and intermediate-risk prostate cancer, 99 percent of men are living cancer-free and with excellent quality of life, according to a University of Florida Proton Therapy Institute study. Three-quarters of those with high-risk prostate cancer are also disease-free.
Schizophrenia enters the molecular diagnostics era
2/13/2014
With a drop of blood and some laboratory analyses, doctors have been able to tell patients whether they suffer from diabetes or some sort of cancer. Measuring changes in the cells or molecules of human tissues or fluids, by detecting so-called biomarkers, has aided the diagnosis of various diseases for some time.
New target isolated for acute myeloid leukemia drug development
2/13/2014
There are potentially effective treatments for acute myeloid leukemia (AML), but they only work in 20 to 40 percent of cases.
First observation of human HAT, key proteins in numerous pathologies
2/13/2014
Researchers at IRB Barcelona, BSC, and the University of Bern observe the first structure of a human HAT at low resolution.HAT amino acid transporters are involved in pathologies such as aminoacidurias, cancer, viral infections and cocaine addiction.
Potential for targeting aggressive breast cancers shown by new UK study
2/13/2014
A new study led by University of Kentucky Markey Cancer Center researcher Peter Zhou shows that targeting Twist, a nuclear protein that is an accelerant of the epithelial-mesenchymal transition (EMT) program in human cells, may provide an effective approach for treating triple-negative breast cancer.
Bladder cancer subtypes genetically similar to breast cancer subtypes
2/13/2014
Researchers at the UNC School of Medicine conducted a comprehensive genetic analysis of invasive bladder cancer tumors to discover that the disease shares genetic similarities with two forms of breast cancer.
A panel of 55 genes, almost all of which are impacted by the loss of a particular protein, appears to predict if breast cancer will become invasive, leading to poorer survival, researchers at Georgetown Lombardi Comprehensive Cancer Center report in PLOS ONE.
New target isolated for acute myeloid leukemia drug development
2/13/2014
There are potentially effective treatments for acute myeloid leukemia (AML), but they only work in 20 to 40 percent of cases.
Key cellular pathway identified in prostate cancer
2/13/2014
Mayo Clinic researchers have shed light on a new mechanism by which prostate cancer develops in men. Central to development of nearly all prostate cancer cases are malfunctions in the androgen receptor - the cellular component that binds to male hormones.
The challenge of accurate diagnosis of Rare Cancers
2/13/2014
Inaccurate diagnosis is a major obstacle for the proper treatment of patients with rare cancers. A Consensus on Improving the Pathologic Diagnosis of Rare Cancers (1) was presented today by Rare Cancers Europe, together with the European Society for Medical Oncology (ESMO) and the European Society of Pathology (ESP) in Brussels.